Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Roche s AmpliChip, Affy s Reader for IVD Use; Agency Says Approval Paves Way for More Tests

NEW YORK, Dec. 27 (GenomeWeb News) - In a significant step for pharmacogenomics in general and microarray-based diagnostics in particular, the US Food and Drug Administration has cleared Roche's AmpliChip CYP450 DNA chip and Affymetrix's GeneChip 3000Dx chip reader as an in vitro diagnostic.

 

The approval, announced in an FDA statement on Dec. 23, marks the first time that a DNA chip reader has won FDA clearance for IVD use. The agency also said the clearance may open the door for additional molecular diagnostics based on microarrays to be sold nationwide.

 

The chip and its reader were approved for sale in the European Union in September.

"The FDA's decision is another milestone demonstrating Affymetrix' commitment to clinical diagnostic products," Stephen Fodor, chairman and CEO of Affymetrix, said in a statement today.

As GenomeWeb News  reported earlier this month, Affy and Roche had separately filed with the FDA their AmpliChip products. A Roche spokesperson told GenomeWeb News at the time that the company is "hoping to see [FDA] clearance [of the Affy reader] in 2005." He did not comment on when Roche expects the AmpliChip to be cleared.

 

"Physicians can use the genetic information from this test to prevent harmful drug interactions and to assure drugs are used optimally, which in some cases will enable patients to avoid less effective or potentially harmful treatment choices," Lester Crawford, acting FDA commissioner, said in the agency's statement.

 

The FDA said that the AmpliChip "is the first DNA microarray test to be cleared by the FDA and its clearance paves the way for similar microarray-based diagnostic tests to be developed in the future."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.